Free tool
FAERS Monitor: Veregen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021902 or its brand name (Veregen, Sinecatechins). Reports on generic versions are filed under their own applications.
Reports
54
Serious
30
56% of reports
Hospitalization
13
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cellulitis6
- application site pain5
- drug ineffective5
- pain4
- product use issue4
- application site erythema3
- erythema3
- off label use3
- pruritus3
- rash3
- application site discharge2
- application site pruritus2
- application site ulcer2
- condition aggravated2
- genital herpes2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 4 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 10 |
| 2019 | 8 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 7 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,105 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site ulcer | 2 | 1104.5 | 282.9 | 1,236 |
| application site discharge | 2 | 676.9 | 173.5 | 757 |
| genital herpes | 2 | 510.0 | 130.8 | 570 |
| application site painSignal | 5 | 88.4 | 38.4 | 349 |
| cellulitisSignal | 6 | 46.4 | 21.8 | 223 |
| application site erythemaSignal | 3 | 44.6 | 14.8 | 88 |
| application site pruritus | 2 | 34.3 | 8.8 | 36 |
| product use issueSignal | 4 | 8.3 | 3.2 | 19 |
| erythemaSignal | 3 | 5.7 | 1.9 | 7 |
| pruritus | 3 | 3.0 | 1.0 | 2 |
| rash | 3 | 2.7 | 0.9 | 2 |
| condition aggravated | 2 | 2.6 | 0.7 | 1 |
| pain | 4 | 2.5 | 1.0 | 2 |
| drug ineffective | 5 | 1.5 | 0.6 | 0 |
| off label use | 3 | 1.3 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.